Last $1.66 USD
Change Today +0.07 / 4.40%
Volume 240.3K
ATHX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

athersys inc (ATHX) Snapshot

Open
$1.60
Previous Close
$1.59
Day High
$1.67
Day Low
$1.59
52 Week High
01/9/14 - $4.33
52 Week Low
04/28/14 - $1.08
Market Cap
127.9M
Average Volume 10 Days
348.1K
EPS TTM
$-0.51
Shares Outstanding
77.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ATHERSYS INC (ATHX)

Related News

No related news articles were found.

athersys inc (ATHX) Related Businessweek News

No Related Businessweek News Found

athersys inc (ATHX) Details

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

56 Employees
Last Reported Date: 03/13/14
Founded in 1995

athersys inc (ATHX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $568.8K
President, Chief Operating Officer and Secret...
Total Annual Compensation: $455.4K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $452.9K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $281.3K
Executive Vice President of Regenerative Medi...
Total Annual Compensation: $383.0K
Compensation as of Fiscal Year 2013.

athersys inc (ATHX) Key Developments

Athersys, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Athersys, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenues of $707,000 against $326,000 a year ago. Loss from operations was $7,389,000 against $6,842,000 a year ago. Net loss and comprehensive loss was $11,484,000 or $0.15 per basic and diluted share against $9,388,000 or $0.18 per basic and diluted share a year ago. The increase in revenues primarily reflects $421,000 increase in its grant revenue. Grant revenue has fluctuated from period to period due to the timing of grant-related activities and with the award and expiration of grants. The increased net loss reflects the $381,000 increase in revenues, offset by, first, the $924,000 million increase in R&D and G&A expenses, which included an increase of $463,000 in noncash stock-based compensation expense; and second, the impact of a $1.6 million increase in noncash expense from the change in fair value of its warrant liabilities. Cash used in operating activities was $7.1 million compared to $6.1 million in the first quarter of 2013.

Athersys, Inc. Announces Results from Phase 2 Study of MultiStem Cell Therapy for Ulcerative Colitis

Athersys, Inc. announced interim results from the Phase 2 clinical study of the administration of Athersys' MultiStem(R) cell therapy to treatment refractory ulcerative colitis (UC) patients being conducted by Pfizer, Inc. The study results demonstrate favorable safety and tolerability for MultiStem through 8 weeks following treatment. However, the cell therapy failed to show meaningful benefit, following a single administration, in patients suffering from chronic, moderate-to-severe UC who have failed other therapies. These results reflect patient data 8 weeks following cell therapy or placebo administration and include the primary efficacy endpoints for the study. Additional 16-week results, including data about the impact from a second round of dosing for a subset of patients, longer term secondary clinical endpoints, and biomarker evaluation will be available after additional analysis has been completed. Data highlights from the 8-week interim analysis include: MultiStem cell therapy demonstrated favorable tolerability and safety profile through 8 weeks following treatment; In this chronic, advanced UC patient population, a single IV administration of MultiStem did not show a statistically significant improvement compared to placebo in the primary efficacy endpoints -- change in endoscopic score from baseline as measured by modified Baron score at 8 weeks and change in Mayo rectal bleeding subscore from baseline at 4 and 8 weeks; and At 4 weeks, the proportion of responders on MultiStem was significantly greater than placebo but the benefit was offset by declines in a minority of MultiStem-treated patients such that overall benefit at all time points measured was not significant. Multiple additional secondary endpoints at week 4 and week 8 were also explored and there were no significant differences observed between the two groups including clinical remission and clinical response.

Athersys, Inc., Annual General Meeting, Jun 17, 2014

Athersys, Inc., Annual General Meeting, Jun 17, 2014., at 08:00 Eastern Daylight. Location: Renaissance Cleveland Hotel. Agenda: To elect the seven Directors nominated by the Board of Directors; to ratify the appointment of Ernst & Young LLP as company's independent auditors for the fiscal year ending December 31, 2014; and to approve, on an advisory basis, named executive officer compensation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATHX:US $1.66 USD +0.07

ATHX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $2.75 USD -0.03
Cytomedix Inc $0.39 USD -0.009
Cytori Therapeutics Inc $2.20 USD +0.10
Pluristem Therapeutics Inc $2.93 USD -0.049
StemCells Inc $1.73 USD -0.005
View Industry Companies
 

Industry Analysis

ATHX

Industry Average

Valuation ATHX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.8x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATHERSYS INC, please visit www.athersys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.